Pancreatic Cancer Research

ResearcherGuangdong Academy of Medical SciencesActive in the last 2 years

Rufu Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1883-1780; OpenAlex author ID A5101607614. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers

Papers 8

  1. Liver diseases, transaminases, and hepatobiliary-pancreatic cancer risk: a cohort and Mendelian randomisation study using data from UK Biobank. Last author DOI 10.1136/bmjgast-2025-001870↗
  2. EIF4E-mediated biogenesis of circPHF14 promotes the growth and metastasis of pancreatic ductal adenocarcinoma via Wnt/β-catenin pathway. Last author DOI 10.1186/s12943-025-02262-5↗
  3. Unexpected complete remission after recurrence in pancreatic cancer: a case report on comprehensive multimodal therapy. Co-author DOI 10.3389/fonc.2025.1582673↗
  4. Endosomal Trafficking Bypassed by the RAB5B-CD109 Interplay Promotes Axonogenesis in KRAS-Mutant Pancreatic Cancer. Last author DOI 10.1002/advs.202405092↗
  5. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. Co-author DOI 10.1186/s13046-023-02854-3↗
  6. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway. Last author DOI 10.1186/s13046-021-02237-6↗
  7. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis. Co-author DOI 10.1186/s12943-020-01196-4↗
  8. circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01205-6↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangyou Zheng · 4 shared papers, 2022–2025 · strength 0.79
  2. Rihua He · 3 shared papers, 2023–2025 · strength 0.64
  3. Yuming Luo · 4 shared papers, 2020–2024 · strength 0.56
  4. Zhuo Kui Wu · 2 shared papers, 2024–2025 · strength 0.49
  5. Chao Yu · 2 shared papers, 2024–2025 · strength 0.49
  6. Zhou Fang · 2 shared papers, 2024–2025 · strength 0.49
  7. Chengyuan Hu · 2 shared papers, 2025 · strength 0.48
  8. Huimou Chen · 2 shared papers, 2025 · strength 0.48
  9. Changhao Chen · 3 shared papers, 2020–2024 · strength 0.40
  10. Zhihua Li · 3 shared papers, 2020–2022 · strength 0.36
  11. Chonghui Hu · 2 shared papers, 2022–2023 · strength 0.31
  12. Renpeng Xia · 2 shared papers, 2022–2023 · strength 0.31
  13. Liangtang Zeng · 1 shared paper, 2025 · strength 0.30
  14. Zhiqiang Fu · 2 shared papers, 2020–2023 · strength 0.26
  15. Quanbo Zhou · 2 shared papers, 2020–2022 · strength 0.25
  16. Yong Jiang · 1 shared paper, 2025 · strength 0.21
  17. Yuan Yuan · 1 shared paper, 2025 · strength 0.21
  18. Xiaofeng Guo · 2 shared papers, 2020 · strength 0.21
  19. Yao Kong · 2 shared papers, 2020 · strength 0.21
  20. Min Yu · 1 shared paper, 2024 · strength 0.19
  21. Jiabin Yang · 1 shared paper, 2024 · strength 0.19
  22. Dingwen Zhang · 1 shared paper, 2024 · strength 0.19
  23. Yu Zhou · 1 shared paper, 2023 · strength 0.16
  24. Shuxin Sun · 1 shared paper, 2023 · strength 0.16
  25. Hongcao Lin · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.